HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

treatment regimen without compromising efficacy.

"This phase II study evaluated DVd as an alternative to the VAD regimen. With DVd, DOXIL is administered as a one hour infusion (compared to a 96 hour infusion with VAD, which also requires indwelling venous access), and vincristine as an IV push every 28 days. The results from this study are encouraging and further study of the DVd regimen in multiple myeloma is warranted," said Mohamad A. Hussein, M.D., Director of the Multiple Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center, the lead investigator of the study.

About Multiple Myeloma and DOXIL
There are more than 14,600 new cases of myeloma in the U.S. each year, representing 20 percent of blood cancers and 1 percent of all types of cancer. Multiple myeloma is a cancer of plasma cells. Plasma cells are normally present in the bone marrow and are responsible for antibody production in response to infection and other immune triggering events. In myeloma, a defective plasma cell (myeloma cell) gives rise to the much larger number of myeloma cells which build up in the bone marrow. This process disrupts the normal immune system as well as displacing the normal bone marrow cells. 1

Indication
DOXIL is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. DOXIL also is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy.

These indications are based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, suc
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... BioPharma Selling Solutions (Spectra) is a new Contract ... experience, expertise, operational delivery and customer focus to ... in concert with industry leading commercial experts, the ... needs of its clients by providing value-based creative ... non-personal promotion. --> ...
(Date:2/11/2016)... 2016 --> ... (OTCQB: PSID), a life sciences company focused on ... subsidiary, which markets the Caregiver® FDA-cleared non-contact thermometer, ... January 2016, including entering into agreements with five ... growth, and establishing several near-term pipeline opportunities. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells ... in Quito, Ecuador. The new facility will provide advanced protocols and state-of-the-art techniques ... the world. , The new GSCG clinic is headed by four prominent ...
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
Breaking Biology Technology:
Cached News: